Brook.ai’s $28M Raise: Taking On Medtronic in RPM

Brook.ai just closed a $28 million Series B led by UMass Memorial Health and Morningside, pushing the Seattle-based remote care startup deeper into a fiercely competitive $8.4 billion market dominated by medical device giants.

But here's the twist—Brook isn't selling wearables. It's selling something far more valuable: clinical outcomes backed by AI that actually works.

Why a Hospital System Led This Round?

When your lead investor is the customer, you're doing something right. UMass Memorial Health didn't just write a check—they validated Brook's model after deploying it across their patient population.

The results? A jaw-dropping 90% reduction in congestive heart failure readmissions and 80% improvement in hypertension control within six weeks. Those aren't vanity metrics. They're the kind of numbers that make CFOs and chief medical officers pay attention.

Founded in 2015 by Oren Nissim—the entrepreneur who sold mobile navigation company Telmap to Intel—Brook combines AI trained on 5 million patient conversations with dedicated remote clinical teams.

Unlike traditional remote patient monitoring (RPM) platforms that dump data dashboards on overworked clinicians, Brook delivers full-service care management. Think of it as RPM meets concierge medicine, powered by AI that knows when to escalate and when to nudge.

The $8.4B Market Nobody Owns Yet

Brook enters a market projected to explode from $1.96 billion (2024) to $8.43 billion by 2030—a 27.5% CAGR that's attracting everyone from Medtronic to scrappy healthtech startups.

The funding accelerates product expansion into new chronic conditions, scales engineering capacity, and fuels commercial growth.

Funding History

The Risk Nobody's Talking About

Brook's biggest competitive threat isn't Medtronic's sensor tech or Biofourmis algorithms—it's reimbursement uncertainty.

RPM billing codes are lucrative today, but CMS and private payers constantly tweak coverage rules.

If reimbursement tightens, Brook's unit economics could crater fast. The company must prove its value-based care ROI transcends fee-for-service billing before payers change the rules.

Company Snapshot

What's Next for Brook.ai?

Brook must prove it can scale beyond early-adopter health systems without diluting clinical quality. The company faces brutal competition from better-funded rivals with decades of provider relationships.

But if Brook's AI-plus-human model delivers consistent outcomes at scale, it could redefine remote care—and force the Medtronics of the world to play catch-up. The clock is ticking.

Connect With Brook.ai